Cellect entered into stem cell collaboration with denovoMATRIX

| By | Drug Development, R&D, Stem Cells
0
61

Cellect Biotechnology, an Israeli developer of a novel stem cell production technology, signed a collaboration and material transfer agreement with the denovoMATRIX group of the Technische Universität Dresden (TU Dresden).

TU Dresden and its Center for Regenerative Therapies Dresden (CRTD), is one of the leading centers for stem cell research in Germany. The two entities believe that the combination of both proprietary technologies may result in significant enhancement of the overall stem cell selection and expansion processes.

According to the agreement, the team of denovoMATRIX employed by TU Dresden will conduct examinations into the tentative synergy between Cellect’s ApoGraft™ and the denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine. To that end, a denovoMATRIX scientist will conduct a line of experiments in Cellect’s R&D facility in Israel.

In the event of successful completion of the evaluation stage, both sides agreed to negotiate in good faith a potential mutual development agreement, for the development of a stem cell related product. Cellect will have the sole discretion on determining the level of success of the evaluation stage.

Cellect’s technology is expected to provide research, hospitals and pharma companies with the tools to rapidly isolate stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company’s current clinical trial is aimed at bone marrow transplantations in cancer treatment.

SOURCE: cellect
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.